BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

ImmunAdd Therapeutics - SPARK

 

ImmunAdd Therapeutics - SPARK

Company Info

Name /ImmunAdd Therapeutics - SPARK

Address /

Website /

Expecting startup year /2021/07

No. of team members /5

Presenter

Name /Pi-Hui Liang

Title /Research Director/ Professor

Email /phliang@ntu.edu.tw

Telephone /(Work) 02-33668695

Fax /

Mobile /0932187796

Company Type

Pharmaceutical

About the Company

ImmunAdd Therapeutics is a start-up company dedicated to provide solution of vaccine by adjuvant design and manufacturing. Adjuvants are critical components that are added to many vaccines to improve the immune responses.

Brief Description of main products or services

Adjuvants can make vaccines effective, but very few can efficiently enhance T-cell responses, and even recently approved adjuvants are characterized by dose-limiting toxicities and structural instability. We are commercializing IA-05, a novel saponin-based vaccine adjuvant that elicits better antigen-specific T-cell responses than existing adjuvants and has a promising safety profile. IA-05 is a saponin-based adjuvant with proven efficacy and safety and patent protection until 2038, including its composition, synthesis, and use. We have demonstrated its effect in boosting better cellular immunity in combination with HPV Vaccines, SARS-CoV-2 Vaccine, intranasal Flu vaccine, and cancer vaccine. We are seeking partners to complete pre-clinical development of IA-05 and its formulation. Our US-and Taiwan-based team includes CMC, regulatory, and scientific experts who have previously brought a vaccine candidate through clinical trials.

Contact Person

Name /Pi-Hui Liang

Email /Phliang@ntu.edu.tw

Phone /0932187796